Leukotriene E4
Based on 1 publication(s) in Google Scholar
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.80%
- CAS. Nr.: 75715-89-8
- Formel: C23H37NO5S
- Molecular Weight:439.61
-
Speicherung:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
-
Help & FAQs
-
HY-113456
Leukotriene D4Bronchoconstrictor -
HY-113446
Leukotriene C4Endogenous Metabolite -
HY-125527
Resolvin D1Endogenous Inflammation Mediator -
HY-107609
BAY-u 9773Cysteinyl-Leukotriene Receptor Antagonist -
HY-117853
Atreleuton5-Lipoxygenase Inhibitor -
HY-17492
ZafirlukastLeukotriene Receptor Antagonist -
HY-13315A
MontelukastCysLT1 Antagonist -
HY-13315
Montelukast sodiumCysltr1 Antagonist -
HY-19989A
MK-571 sodiumABCC1/MRP4 Inhibitor -
HY-13315AR
Montelukast (Standard)CysLT1 Antagonist -
HY-15744
LY255283LTB4 Receptor Antagonist -
HY-105484
U-75302LTB4 inhibitor
Publications Citing Use of MedChemExpress (MCE) Leukotriene E4
MoreAlle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
|
Human Endogenous Metabolite |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
9.83 μM
Compound: Leukotrien E4
|
TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells
TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells
|
[PMID: 11306690] |
In Vitro
Leukotriene E4 induces only a very weak, non-sustained intracellular calcium mobilization response in LUVA human mast cells, with no detectable EC50[1].
Leukotriene E4 induces concentration-dependent intracellular calcium mobilization in HEK293T cells transfected with CYSLTR1, with an EC50 of 83.2 nM[1].
Leukotriene E4 (100 nM; 2-60 min) induces sustained phosphorylation of Erk in LAD2 human mast cells, and the activation signal remains detectable after 60 minutes[1].
Leukotriene E4 (100 nM; 2-60 min) induces transient phosphorylation of Erk in LUVA human mast cells, with no sustained activation observed within 60 minutes[1].
Leukotriene E4 (1-100 nM; 15 min) induces PTX-sensitive, MK571-resistant ERK phosphorylation in Chinese hamster ovary cells stably expressing human P2Y12 receptors, with activation initiating at 1 nM and reaching a plateau at 100 nM[2].
Leukotriene E4 (500 nM) induces calcium influx in LAD2 human mast cells, and this response is not inhibited by the P2Y12 antagonist 2-MesAMP (HY-125989)[2].
Leukotriene E4 (100 nM) induces the production of PGD2 in the human mast cell line LAD2, and the generation of this product is completely dependent on the P2Y12 receptor[2].
Leukotriene E4 (1 μM; 10 min) does not induce the expression of CD62P (an activation marker) in human blood platelets[2].
Leukotriene E4 (100 nM; 2-6 h) induces only extremely weak CCL4 mRNA and protein expression in LUVA human mast cells, with much lower potency relative to LTD4[1].
The induction of CCL4 mRNA expression in human mast cell line LAD2 by Leukotriene E4 (100 nM; 2 h) depends on the MEK/Erk pathway and intracellular/extracellular Ca2+, but is independent of Gi/o proteins or the PPAR-γ signaling pathway[1].
Leukotriene E4 (100 nM; 5 min-2 h) requires prolonged exposure (2 h) to induce full CCL4 mRNA expression in LAD2 human mast cells, whereas short-term exposure (5 min) only elicits weak activity[1].
Leukotriene E4 (100-500 nM; 6 h) induces high levels of MIP-1β production in LAD2 human mast cells, and this production process is mainly dependent on the P2Y12 receptor; the P2Y12 antagonist 2-MesAMP inhibits more than 50% of its production, while P2Y12 shRNA knockdown almost completely blocks this production process[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 75715-89-8
-
Appearance Liquid
-
Molecular Weight 439.61
-
Formel C23H37NO5S
-
Color Colorless to light yellow
-
SMILES
CCCCC/C=C\C/C=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O
-
Synonyms
LTE4
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Solution, -20°C, 2 years
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Dec 18;16(1):11205. PMID: 41413034
Reinheit & Dokumentation
-
Data Sheet (238 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Leukotriene E4 Related Classifications
HY-113465 Related Classifications
Powered by Bioz